Back to results
TerminatedPhase 2

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

NCT00130507

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Spanish Breast Cancer Research Group (GEICAM)

San Sebastián de los Reyes, Madrid, Spain

View on ClinicalTrials.gov
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab — TrialFind